Quigley Counts On Delivery Technology Partner To Expand Consumer Business
This article was originally published in The Tan Sheet
Executive Summary
Quigley Corp. picks delivery technology developer Phosphagenics to help grow its sales after curbing its Rx research to expand its consumer business beyond Cold-EEZE and its other natural health care lines
You may also be interested in...
CEO Karkus Talks Cold-EEZE Turnaround At “Lean, Mean” ProPhase Labs
In an interview, ProPhase Labs CEO Ted Karkus talks about the ongoing turnaround of Cold-EEZE zinc lozenges, ProPhase’s flagship brand, as well as efforts to launch new products and restore relationships with retailers.
CEO Karkus Talks Cold-EEZE Turnaround At “Lean, Mean” ProPhase Labs
In an interview, ProPhase Labs CEO Ted Karkus talks about the ongoing turnaround of Cold-EEZE zinc lozenges, ProPhase’s flagship brand, as well as efforts to launch new products and restore relationships with retailers.
Quigley now ProPhase Labs
The maker of Cold-EEZE zinc lozenges changes its name to ProPhase Labs Inc., following a shareholder vote May 5. Company shares now trade on NASDAQ under the symbol "PRPH." CEO Ted Karkus said the corporate re-branding will include redesigned packaging for Cold-EEZE and Kids-EEZE cold remedies. Since ousting founder Guy Quigley in June 2009, Karkus has shaken things up at the Doylestown, Pa., firm, including forming an OTC joint venture with delivery technology developer Phosphagenics (1"The Tan Sheet" March 29, 2010)